The new guidelines of the American Headache Society (“AHS”) have provided an evidence-based assessment, on the basis of a systematic review of Class I studies, for the treatment of acute migraine, an important public health problem with a 20.2% average prevalence (Headache. 2015;55(1):3-20).
Diclofenac Potassium Powder for Oral Solution (Immediate Release Technology, IRT) has been established as “effective” (Level A) for the therapy of acute migraine attacks and met the primary outcomes, leaving a greater number of patients headache-free at 2 hours and improving key associated symptoms of acute migraine, as freedom from nausea and from light/sound sensitivity, compared to placebo.
Immediate Release Technology (IRT) has been developed and patented by APR and is characterized by the unique blending of excipients: a special ratio between diclofenac and bicarbonate that create a micro-environmental at gastro-intestinal level, to ensure more rapid and regular absorption and faster onset of action of diclofenac in APR formulations (powder for oral solution, tablets and oral solution) compared with conventional preparations.
Diclofenac Potassium Powder for Oral Solution is marketed in USA and Canada by the publicly traded companies Depomed Inc. and Tribute Pharmaceuticals Inc. respectively under the brand name Cambia®; in addition this product is marketed by Novartis Pharma AG in several countries beyond North America under various brand names such as Voltfast® and Catafast®